Skip to main content
OKYO Pharma Ltd logo

OKYO Pharma Ltd — Investor Relations & Filings

Ticker · OKYO ISIN · US6793451088 US Manufacturing
Open in API
Filings indexed 274 across all filing types
Latest filing 2024-03-21 Regulatory Filings
Country US United States of America
Listing US OKYO

About OKYO Pharma Ltd

https://okyopharma.com/

OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for inflammatory eye diseases and chronic pain. The company's primary focus is on addressing significant unmet medical needs in neuropathic corneal pain (NCP) and dry eye disease (DED). Its lead product candidate, Urcosimod (OK-101), is a novel G protein-coupled receptor (GPCR) agonist that targets the chemerin receptor to produce anti-inflammatory and pain-reducing effects. OKYO is the first company to receive Investigational New Drug (IND) clearance from the FDA to clinically evaluate a drug specifically for NCP, a condition with no approved treatments. Urcosimod has also been granted Fast Track Designation by the FDA for the treatment of NCP.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, with the SEC. It announces a Key Opinion Leader event to discuss upcoming Phase 2 trial efficacy data, with the actual data readout to be announced on March 22, 2024. The document is short (2848 characters) and primarily serves as an announcement of an event and forthcoming data, not containing substantive financial statements or detailed financial analysis. It also includes a news announcement as an exhibit. Given the length and content, this is not a full financial report or earnings release but rather a regulatory announcement providing information to investors. According to the rules, such documents that announce events or reports without containing the reports themselves are best classified as Regulatory Filings (RNS).
2024-03-21 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It announces that OKYO Pharma LTD will release new efficacy data from a Phase 2 trial and host a Key Opinion Leader event. The document includes an exhibit index referencing a news announcement. The text explicitly states that the information is being furnished and not filed, indicating this is an announcement rather than a full report. The document length is short (2807 characters), and it primarily serves to announce upcoming data release and events, not to provide detailed financial or operational data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-03-20 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It contains an announcement about FDA clearance of an Investigational New Drug application by OKYO Pharma LTD. The document is relatively short (2755 characters) and primarily serves to furnish an announcement (Exhibit 99.1) rather than provide detailed financial data or a comprehensive report. There is no substantive financial statement or detailed analysis present. According to the rules, such filings that are announcements or furnishing of information without full report content should be classified as Regulatory Filings (RNS).
2024-02-09 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, with the SEC. It announces the appointment of distinguished ophthalmologists to the company's Scientific Advisory Board following positive Phase 2 trial results. The document is short (2881 characters) and primarily serves as an announcement rather than a detailed report. It references an attached Exhibit 99.1 which is a news announcement. There are no financial statements or substantive financial data included. The document is not an annual or interim report, nor is it a call transcript or earnings release. It is a regulatory filing providing material company updates but does not fit into more specific categories like management changes (MANG) since it concerns advisory board appointments, which are not typically classified as board or senior management changes. Given the nature and length, and that it is a Form 6-K, the best classification is Regulatory Filings (RNS).
2024-01-31 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, with the SEC. It announces a clinical trial result for OK-101 achieving statistical significance in a Phase 2 trial. The document is short (2546 characters) and primarily serves as an announcement of this news, with an exhibit referenced as a news announcement. There are no financial statements, detailed financial data, or comprehensive reports included. The document is not an annual or interim report, nor a detailed earnings release. It is a regulatory filing used to disclose material information promptly. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-01-08 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, with the SEC. It announces that the company will be presenting at the Biotech Showcase conference and participating in partnering meetings. The document is short (2732 characters) and primarily serves as an announcement of an event rather than containing financial data, management discussion, or detailed report content. It includes a news announcement as Exhibit 99.1 but does not contain the actual presentation or detailed report. According to the MENU VS MEAL RULE, this is an announcement-type filing rather than a full report. Form 6-K filings often serve as Regulatory Filings (RNS) when they provide miscellaneous updates or announcements that do not fit other categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-01-05 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.